Purpose: To decrease symptom burden, improve cognitive function, improve endurance, and decrease fatigue in subjects with post-acute sequelae of COVID-19 (PASC) or "long-hauler" COVID using amantadine. If amantadine use is determined to be efficacious in this population, the findings of this study will be used towards a subsequent randomized control trial.

开始日期2025-06-01

申办/合作机构

The University of Texas Southwestern Medical Center

CTRI/2025/04/085165

/ Not yet recruitingN/AIIT

Evaluation of efficacy of add on oral amantadine in children and adolescents with subacute sclerosing panencephalitis aged less than 18years: A randomized controlled trial - nil

开始日期2025-05-21

申办/合作机构

All India Institute of Medical Sciences

NCT06817200

/ Not yet recruiting临床2期IIT

The Effect of Amantadine as add-on Therapy for Motor Fluctuations in Advanced Parkinson's Disease: a Randomized Double-blinded Placebo-controlled Trial

Motor fluctuations are identified as the most challenging symptoms by parkinson disease patients. A recent post-hoc analysis of ADS-5012 trials (new formulation of ER Amantadine), revealed a significant improvement in OFF-time. No randomized clinical trial has ever specifically investigated to date the effect of amantadine IR on motor fluctuations. The main objective of this study is to evaluate the effect of amantadine (300 mg/day) as add-on therapy for the treatment of motor fluctuations (Off-time) in advanced Parkinson's disease patients versus placebo after 3 months of treatment.

开始日期2025-05-01

申办/合作机构

Toulouse University Hospital

100 项与盐酸金刚烷胺相关的临床结果

登录后查看更多信息

100 项与盐酸金刚烷胺相关的转化医学

登录后查看更多信息

100 项与盐酸金刚烷胺相关的专利（医药）

登录后查看更多信息

10,017

项与盐酸金刚烷胺相关的文献（医药）

2025-10-01·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

Aliphatic amines – Sensing application in aqueous media using supramolecularly stacked acriflavine dye on graphene oxide

Article

作者: Rajendran, Pavitra ; Selvapalam, Narayanan ; Kannan, Jamuna ; Piramuthu, Lakshminarayanan ; Nagarajan, Erumaipatty Rajagounder ; Sivakumar, Shanmugam

Supramolecularly stacked acriflavine dye on graphene oxide (GO-Acy) was utilized for the first time to detect aliphatic amines, making it a highly sensitive and selective material. This method involved developing a distinctive, discriminative, and highly selective fluorescent sensor that displayed a 'turn-on' response to aliphatic amines. The sensor probe operated through supramolecular host-guest interactions between the amines and dyes, enabling the detection of aliphatic amines. Upon the interaction of aliphatic amines with bound Acy dye on graphene oxide, the fluorescent sensor exhibited a release of Acy dyes and a rapid appearance of fluorescence. GO-Acy demonstrated high selectivity for 1,4-butanediamine (BD), exhibiting strong fluorescence intensity and accurately distinguishing it from various aliphatic amines, aromatic amines, and amino acids. The fluorescene emission intensities of GO-Acy at λ_em = 510 nm was observed after exposure to different amines, with an excitation wavelength of GO-Acy at λ_ex = 450 nm. In addition to its high selectivity, the sensor probe also exhibited excellent sensitivity towards BD, with a limit of detection (LOD) of 9.9 nM. This graphene-based material proved to be a highly effective tool for detecting aliphatic amines in aqueous media, requiring no special experiments while providing both good selectivity and sensitivity. Additionally, GO-Acy@CB[7] demonstrated diverse responses to aliphatic amines, suggesting its ability to discriminate between them through fluorescence quenching. GO-Acy has proven effective in monitoring fish products that release amine vapors during decomposition. Furthermore, test paper strips made with GO-Acy could quickly detect amines in actual fish samples, highlighting the potential of GO-Acy for food quality inspection.

2025-10-01·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

Cocrystallization of amantadine hydrochloride with nutrient: Insights into directed self- assembly and optimized biopharmaceutical character by integrating theory and experiment

Article

作者: Wu, Zhi-Yong ; Li, Yan-Tuan ; Zhao, Ming-Yu ; Wang, Ling-Yang ; Bu, Fan-Zhi

In order to make full use of the advantages of phenolic acid nutraceutical p-coumaric acid (COA) in cocrystallizing with antiviral medication amantadine hydrochloride (ADH), further get innovative insights into assembling ADH-nutraceutical cocrystal and optimizing biopharmaceutical characters of ADH by combining experiment with theory, a novel cocrystal, ADH-COA, is prepared and structurally characterized. Single-crystal X-ray diffraction confirms that the cocrystal consists of COA and ADH molecules in a 1:2 ratio, building a three-dimensional supramolecular network strengthened by charge-assisted hydrogen bonds and tightly packed patterns, which is distinguished by two distinct conformations H-1 and H-2 arising from neutral COA molecules with different counter-ions of ADH within the lattice. These features endow the cocrystal with promoting charge dispersion and polarity reduction, resulting in 37.11 ∼ 41.39 % solubility reduction under different pH conditions versus raw ADH, contributing to mitigating side effects associated with excessive solubility of ADH. Such change of in vitro property, in turn, optimizes in vivo pharmacokinetics, showcasing the lengthened half-life and enhanced 1.45-fold bioavailability. Emphatically, these experimental findings are corroborated by DFT-based theoretical models, demonstrating some positive correlations between macroscopic properties and microstructures of the cocrystal. Thereby, the dual-optimization of in vivo/vitro properties of ADH allows to be fulfilled through the cocrystallization-driven strategy.

2025-09-01·Current computer-aided drug design

Molecular Dynamics Simulation of SARS-CoV-2 E Ion Channel: The Study of Lone Protein and its Conformational Changes in Complex with Potential Cage Inhibitors

Article

作者: Tkachenko, Ilya Michailovich ; Shiryaev, Vadim Andreevich ; Ivleva, Elena Alexandrovna ; Zaborskaya, Maria Sergeevna ; Osyanin, Vitaly Alexandrovich ; Klimochkin, Yuri Nikolaevich

Background::

The coronavirus E ion channel has previously been studied as a potential target for antiviral therapy, with several compounds found to bind to the channel. However, these compounds have low activity, searching for effective E ion channel inhibitors of great importance.

Objective::

This study aimed to develop a computational approach for designing ligands for the coronaviral E ion channel and identify potential inhibitors based on this approach.

Methods::

The structure of the E-ion channel was refined using molecular dynamics, and the pore responsible for binding cage compounds was selected as the inhibitor-binding site. Potential inhibitor structures were identified using molecular docking, and their binding was confirmed using molecular dynamics simulations.

Results::

A number of potential SARS E ion channel inhibitors have been identified, and the binding modes and possible mechanisms of action of these inhibitors have been clarified.

Conclusion::

This study presents a computational approach that can be used to design ligands for E ion channels and identify potential inhibitors, providing valuable insights into the development of new antiviral therapies. The behavior of the E protein pentamer of SARS-CoV-2 in its native environment was investigated using Molecular Dynamics (MD), resulting in an equilibrated structure that could be used to develop new inhibitors through molecular docking. Simulation of the MD of E-channel complexes with amantadine analogues allowed for the identification of the main types of ligand-protein interactions that are responsible for the good binding of ligands within the channel's inner chamber.

111

项与盐酸金刚烷胺相关的新闻（医药）

2025-05-29

·PRNewswire

INBRIJA Positioned for Stronger Market Penetration as Demand Grows for Inhaled Parkinson's Therapy| DelveInsight

INBRIJA, a dopamine replacement therapy for off periods in Parkinson's disease, holds significant market potential due to its ability to provide rapid relief from motor symptoms. With the increasing prevalence of Parkinson's globally, the demand for effective treatments is growing. INBRIJA offers a novel, non-oral alternative, positioning it well in the market for patients who struggle with traditional therapies. LAS VEGAS, May 29, 2025 /PRNewswire/ -- DelveInsight's " INBRIJA Market Size, Forecast, and Market Insight Report" highlights the details around INBRIJA, which consists of a dry powder formulation of levodopa for oral inhalation with the INBRIJA inhaler. The report provides product descriptions, patent details, and competitor products (marketed and emerging therapies) of INBRIJA. The report also highlights the historical and forecasted sales from 2020 to 2034 segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Acorda Therapeutics' INBRIJA (Levodopa) Overview INBRIJA is an inhalable dry powder formulation of levodopa designed for use with the INBRIJA inhaler. The medication is delivered via white hypromellose capsules, each containing 42 mg of levodopa in a spray-dried powder form, along with excipients such as 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and sodium chloride. Levodopa, the active ingredient in INBRIJA, is an aromatic amino acid with the chemical name (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid. Its molecular formula is C₉H₁₁NO₄, and it has a molecular weight of 197.19 g/mol. INBRIJA is indicated for the intermittent relief of OFF episodes in patients with Parkinson's disease who are already receiving treatment with carbidopa/levodopa. It is not intended to replace regular carbidopa/levodopa therapy but is used to reduce OFF periods and improve motor symptoms. Each therapeutic capsule is used with a specially designed plastic inhaler featuring a blue body, blue cap, and a white mouthpiece. Patients may use INBRIJA up to five times per day, with the maximum daily dose limited to 420 mg. Learn more about INBRIJA projected market size for Parkinson's disease @ INBRIJA Market Potential Parkinson's disease is a chronic and progressive neurological condition that primarily affects the ability to control movement. It is caused by the gradual loss of dopamine-producing neurons in the brain, particularly in the substantia nigra—a region vital for regulating voluntary muscle activity. According to DelveInsight, there were approximately 3 million diagnosed prevalent cases of Parkinson's disease across the 7MM in 2024, with the United States accounting for about 45% of these. Although there is currently no cure, symptom management involves a mix of medications and supportive therapies. Treatment typically includes physical, occupational, and speech therapy, and certain patients may benefit from surgical interventions. Complementary therapies are also sometimes used to help manage specific symptoms. Commonly used drugs for Parkinson's include levodopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors, amantadine, anticholinergics, and adenosine A2A receptor antagonists. These medications primarily aim to alleviate motor symptoms, which significantly impact patients' quality of life. DelveInsight estimates the Parkinson's disease market in the 7MM to have been worth USD 3.5 billion in 2024. DelveInsight's analysis forecasts market growth due to the introduction of emerging therapies, expecting a rise in market size during the study period (2020–2034). The anticipated increase in market size is driven by advancements in treatment options, greater healthcare access, and a rising prevalence of the condition, which together foster higher demand for innovative and effective therapies. Discover more about the Parkinson's disease market in detail @ Parkinson's Disease Market Report Emerging Competitors of INBRIJA Some of the emerging competitors to INBRIJA in the Parkinson's disease treatment landscape include Solengepras (Cerevance) , Buntanetap (Annovis Bio) , Prasinezumab (Roche/Protherna) , JOTROL (Jupiter Neurosciences), Glovadalen (UCB Biopharma), and others. In April 2025, Cerevance reported that the pivotal Phase III ARISE trial evaluating Solengepras as an adjunctive treatment for Parkinson's disease was ongoing, with topline results expected in the first half of 2026. Cerevance's GPR6 antagonist, Solengepras, did not meet its primary endpoint in the Phase II ASCEND trial as a monotherapy for early, untreated Parkinson's disease patients, demonstrating only a modest and statistically non-significant improvement compared to placebo, as reported at AD/PD 2025. According to the results presented at AD/PD 2025, Buntanetap has been shown to prevent cognitive decline across the entire treated ITT population. In patients with existing cognitive impairment, it improved cognitive performance along with MDS-UPDRS, WAIS, and CGI-S scores. A meeting with the US FDA to discuss the future development strategy is scheduled for the second Quarter of 2025. The ATLANTIS Phase II trial design for glovadalen was presented at AD/PD 2025, highlighting its potential as a Parkinson's treatment. As a D1PAM, it boosts dopamine signaling without directly activating receptors. To know more about the number of competing drugs in development, visit @ INBRIJA Market Positioning Compared to Other Drugs Key Milestones of INBRIJA In March 2023, Acorda Therapeutics announced that Esteve Pharmaceuticals launched INBRIJA 33 mg (levodopa inhalation powder, hard capsules) in Spain. Esteve launched INBRIJA in Germany in mid-2022. In September 2019, Acorda Therapeutics announced that the European Commission (EC) granted marketing authorization for INBRIJA 33 mg inhalation powder, hard capsules. In Europe, INBRIJA is indicated for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson's disease treated with a levodopa/dopa-decarboxylase inhibitor. The Marketing Authorization approves INBRIJA for use in the 28 countries of the European Union, as well as Iceland, Norway, and Liechtenstein. In December 2018, INBRIJA was approved by the US FDA for intermittent treatment of OFF Episodes in people with Parkinson's taking carbidopa/levodopa. Discover how INBRIJA is shaping the Parkinson's disease treatment landscape @ INBRIJA Inhaler INBRIJA Market Dynamics INBRIJA is a medication used to manage "off" periods in patients with Parkinson's disease who are on a stable regimen of oral levodopa. The market dynamics surrounding INBRIJA are influenced by several factors, including the growing demand for innovative treatments for Parkinson's disease, an aging global population, and the increasing recognition of the importance of managing off periods in patients with Parkinson's. As the number of Parkinson's disease patients continues to rise globally, particularly with the aging Baby Boomer generation, the market for Parkinson's disease therapies is expanding, offering significant growth potential for medications like INBRIJA. One of the key drivers for INBRIJA's market is the unmet need for effective treatments for off periods. Traditional oral levodopa, the mainstay of Parkinson's treatment, can lose efficacy over time, leading to motor fluctuations that result in off periods, during which patients experience a worsening of symptoms such as tremors and rigidity. INBRIJA provides an alternative in the form of an inhaled levodopa treatment that acts rapidly to help manage these periods, offering patients a faster-acting option compared to oral medications. This positioning appeals to both patients and healthcare providers who are looking for ways to improve the quality of life for people with Parkinson's. Despite its promising potential, INBRIJA faces challenges in the market. The primary hurdle is its relatively high cost compared to traditional levodopa treatments, which could limit its accessibility, particularly in regions with limited healthcare resources. Additionally, the need for an inhaler device and potential issues related to device handling and patient compliance could also impact market penetration. Moreover, INBRIJA competes with other therapeutic options in the Parkinson's space, including dopamine agonists and other adjunctive treatments, which means ongoing education and marketing efforts are required to differentiate its unique benefits. In terms of market opportunities, INBRIJA could benefit from increased awareness among healthcare providers about the drug's role in improving patient outcomes during off periods. Collaborations with Parkinson's disease advocacy groups and patient education initiatives could help drive adoption. Furthermore, expanding indications or seeking approval for additional uses could open up new revenue streams and bolster INBRIJA's position in the Parkinson's treatment market. Overall, while the market for INBRIJA faces challenges, the growing demand for better management of Parkinson's symptoms presents opportunities for continued growth and adoption. Dive deeper to get more insight into INBRIJA's strengths & weaknesses relative to competitors @ INBRIJA Market Drug Report Table of Contents Related Reports Parkinson's Disease Market Parkinson's Disease Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson's disease companies, including UCB Biopharma SRL, Novartis, Annovis Bio, Supernus Pharmaceuticals, Inc., Britannia Pharmaceutical, Pharma Two B, Mitsubishi Tanabe Pharma (NeuroDerm), AbbVie, Cerevel Therapeutics, Cerevance, among others. Parkinson's Disease Pipeline Parkinson's Disease Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Parkinson's disease companies, including Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Roche, Brain Neurotherapy Bio, Inc., Modag, Annovis Bio Inc., BioVie Inc., United Neuroscience Ltd., Luye Pharma Group, AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., Nobilis Therapeutics Inc., BlueRock Therapeutics, Taiwan Mitochondrion Applied Technology Co., Ltd., among others. Cell and Gene Therapy in Parkinson's Disease Market Cell and Gene Therapy in Parkinson's Disease Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key cell and gene therapy in Parkinson's disease companies including MeiraGTx, Hope Biosciences, Sumitomo Pharma, Prevail Therapeutics, BlueRock Therapeutics, Voyager Therapeutics, among others. Parkinson's Disease Psychosis Market Parkinson's Disease Psychosis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson's disease psychosis companies, including Sumitomo Pharma America Inc., Vanda Pharmaceuticals, Acadia Pharmaceuticals Inc., Otsuka America Pharmaceutical, Lundbeck LLC, Jazz Pharmaceuticals, Alkahest Inc., Sandoz, Sio Gene Therapies, Axovant Sciences Ltd, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床2期临床结果上市批准临床3期

2025-05-22

·维健医药

WinHealth Pharma and Merz Upgrade Long-Term Partnership

SHANGHAI, May 19, 2025 – WinHealth Pharma Group (WinHealth Pharma) and Merz Therapeutics announced the signing of an enhanced long-term strategic partnership agreement, representing a significant milestone in their longstanding collaboration. This expanded agreement strengthens their strategic presence in the Greater China region and reaffirms their shared commitment to advancing access to innovative, high-quality therapies for a broader patient population.This strategic collaboration ushers in the next phase of partnership between WinHealth Pharma and Merz Therapeutics, advancing into the "2.0 Era". The collaboration has achieved a historic breakthrough in both depth and breadth. The partnership term has been substantially extended, and the product portfolio has been expanded from two to five key offerings, covering prescription medicines, over-the-counter (OTC) products, consumer health brands, and cross-border business. Furthermore, the geographic reach has been broadened from Mainland of China to China’s Hong Kong, Macau, and Taiwan, further extending access to innovative therapies for a larger patient population. This upgrade underscores the profound trust and mutual commitment between both companies, highlighting their unwavering dedication to sustainable, long-term growth in Greater China.At the strategic partnership signing ceremony, the leadership teams from WinHealth Pharma and Merz Therapeutics took a group photoThrough this collaboration, the two companies will further build on their successful partnership in Mainland of China, capitalizing on the proven success of Hepa-Merz® (Ornithine Aspartate Injection) and Contractubex® (Compound Heparin Sodium and Allantoin Gel), while expanding the commercialization rights of these products to China’s Hong Kong, Macau, and Taiwan. The partnership is further solidified with the introduction of new products, including the dermatology OTC brand Contractubex® (Compound Heparin Sodium and Allantoin Gel), PK-Merz® (Amantadine/Amantadine Sulfate) for Parkinson’s disease, and the renowned Pantogar® series for anti-hair loss. This strategic expansion further enriches and strengthens WinHealth Pharma’s portfolio, broadening its reach across prescription medicines, over-the-counter (OTC) products, and consumer health segments.• Hepa-Merz® (Ornithine Aspartate Injection): As an originator therapy, Hepa-Merz® is widely recommended by both domestic and international clinical guidelines as a first-line treatment for hepatic encephalopathy.• Contractubex® (Compound Heparin Sodium and Allantoin Gel): Known for its anti-inflammatory, moisturizing, and wound-healing properties, it is recommended in both domestic and international guidelines for the treatment of scars.• Contractubex® (Compound Heparin Sodium and Allantoin Gel): A leading OTC dermatology brand, Contractubex® Scar Gel is widely used in over 60 countries and is highly recommended by healthcare professionals for scar treatment.• PK-Merz® (Amantadine/Amantadine Sulfate): Used in the treatment of Parkinson’s disease, PK-Merz® helps improve motor symptoms by compensating for neurotransmitter imbalances in the brain and is effective in preventing and treating dyskinesia.• Pantogar® Series Anti-Hair Loss Products: Including capsules, shampoo, and tonic, these products enhance hair growth and provide essential nutrients, treating diffuse hair loss and supporting the natural growth of hair.This expanded collaboration not only solidifies WinHealth Pharma's leadership in the dermatology, hepatology, and neurology therapeutic areas but also injects new momentum into the company's strategic initiatives, driving its continued growth in Greater China and beyond.Andrea von der Lippe, President Region International Markets at Merz Therapeutics, said: "Since the inception of our partnership with WinHealth Pharma in 2017, we have achieved outstanding results. WinHealth Pharma has proven its exceptional commercialization capabilities, extensive market reach, and superior execution, establishing itself as a trusted long-term strategic partner. The deepening of this strategic collaboration not only builds on the strong foundation of our past successes but also paves the way for exciting new opportunities and broader development prospects in the Greater China market. We look forward to continuing our close collaboration with WinHealth Pharma to bring more established and innovative products to market, offering an even broader range of advanced therapeutic options for a wider patient base."Carlos Sese, Senior Director Head of Region APAC at Merz Therapeutics, said: "Our collaboration with WinHealth Pharma is built on a strong foundation of deep trust and a shared vision. We have maintained a close partnership and worked together to successfully bring several key products to market. The further deepening of this strategic partnership not only solidifies our position in Greater China but also opens up a new chapter for future business expansion and the introduction of innovative therapies. This upgrade of our strategic collaboration is not just an extension of our past successes, but a catalyst for unleashing our future potential. We look forward to continuing our close partnership with WinHealth Pharma, driving the development and commercialization of more groundbreaking therapies to meet the increasingly diverse treatment needs of patients."Jack Wang, Chairman of Hong Kong WinHealth Pharma Group, said: " The deepening of our strategic partnership with Merz Therapeutics is a landmark achievement, marking a new chapter in our collaboration across Greater China and unlocking unprecedented opportunities for growth. As a leading biopharmaceutical company with an integrated value chain, WinHealth Pharma remains committed to a patients-first philosophy, concentrating on the development and commercialization of innovative and originator drugs, while addressing the unmet medical needs in the healthcare sector. This strategic advancement will accelerate our market penetration and growth in Greater China, enhance our portfolio in critical therapeutic areas such as hepatology, neurology, and dermatology, driving our continued growth in Asia and global markets. Our unwavering commitment is to deliver groundbreaking therapies that significantly improve patient outcomes and quality of life, paving the way for a broader and brighter future."Oliver Hao, Executive Director and Co-CEO of Hong Kong WinHealth Pharma Group, said: "At WinHealth Pharma, we remain steadfast in our commitment to patients, partners, and employees, which is deeply rooted in our founding principles and corporate mission, driving our sustainable growth on a global scale continuously. This collaboration marks the commencement of a new ‘2.0 era’ in our strategic partnership with Merz Therapeutics. In this new model, both companies are committed to forging a deeper and more long-term collaboration that will not only benefit more patients across Greater China but will also significantly expand the reach and influence of the brands within the partnership’s scope. Moving forward, WinHealth Pharma remains focused on introducing more originator and innovative therapies, providing patients with more effective and accessible treatment options, enhancing their quality of life, and resolutely upholding our patient-centered development strategy."About Merz TherapeuticsMerz Therapeutics is dedicated to improving the lives of patients around the world. With its relentless research, development and culture of innovation, Merz Therapeutics strives to serve unmet patient needs and realize better outcomes. Merz Therapeutics seeks to address the unique needs of people who suffer from movement disorders, neurological conditions, liver disease and other health conditions that severely impact patients’ quality of life.Merz Therapeutics is headquartered in Frankfurt am Main, Germany and is represented in more than 90 countries, with a North America affiliate based in Raleigh, North Carolina. Merz Therapeutics GmbH is part of the Merz Group, a privately held, family-owned company that has dedicated 115 years to developing innovations that serve unmet patient and customer needs.Please visit www.stage.merztherapeutics.com.About WinHealth PharmaFounded in 2006, WinHealth Pharma is a Hong Kong-based biopharmaceutical company with a comprehensive, end-to-end value chain. The company focuses on three core areas: proprietary pharmaceutical products, CSO business, and specialty care, with a strong commitment to the development and commercialization of cutting-edge medicines. Guided by a patient-first philosophy, we are dedicated to delivering breakthrough therapies and innovative healthcare solutions to patients with cardio-renal diseases, hematologic cancers, gastrointestinal diseases, respiratory and infectious diseases, rare diseases, and other unmet medical needs. Our commitment is to improve patients’ lives through transformative treatments. With a well-established presence in China, WinHealth Pharma is actively expanding across Asia and other international markets, building a comprehensive healthcare ecosystem, driving innovation, and addressing the evolving treatment needs of patients. For more information, please visit www.winhealth.hk.END

2025-05-22

·cn.winhealth.hk

维健医药与 Merz Therapeutics 宣布重磅升级长期战略合作，全面拓展大中华区市场

2025年5月19日，上海——香港维健医药集团（以下简称“维健医药”）与 Merz Therapeutics正式宣布签署长期战略合作协议，标志着双方将在大中华区进一步深化战略布局，携手为更多患者提供优质创新的疗法。此次战略合作的签署，标志着维健医药与 Merz Therapeutics 的合作关系全面升级，迈入全新发展的2.0阶段。双方在合作的深度与广度上实现了历史性突破：合作期限大幅延长，合作产品从原有的两款扩展至五款，覆盖处方药、非处方药（OTC）、消费者品牌及跨境业务；与此同时，合作区域亦从中国内地（大陆）拓展至中国香港、澳门和台湾地区，进一步扩大了惠及患者的覆盖范围。此次战略升级不仅彰显了双方深厚的互信基础，也充分体现了维健医药与 Merz Therapeutics 在大中华区携手并进、共同推动长期可持续发展的坚定承诺。在此次战略合作签署仪式上，维健医药与 Merz Therapeutics 管理团队合影通过此次合作，双方将在中国内地（大陆）市场延续对雅博司®（门冬氨酸鸟氨酸注射液）和康瑞保®（复方肝素钠尿囊素凝胶）的成功合作，并将这两款产品的商业化授权范围扩展至中国香港、澳门及台湾地区。在此基础上，新增的合作产品包括：皮肤护理品牌秀碧®（复方肝素钠尿囊素凝胶）、帕金森病治疗药物PK-Merz®（金刚烷胺/硫酸金刚烷胺）以及经典防脱发产品Pantogar®系列，进一步丰富并强化了维健医药在处方药、OTC 及消费者健康领域的产品组合。雅博司®（门冬氨酸鸟氨酸注射液）：作为原研门冬氨酸鸟氨酸注射液，已被国内外多项临床指南推荐为肝性脑病的一线治疗方案。康瑞保®（复方肝素钠尿囊素凝胶）：具有抗炎、保湿、促进创面愈合和抑制瘢痕增生等作用，并被国内外指南共识推荐用于治疗瘢痕。秀碧®（复方肝素钠尿囊素凝胶）：作为皮肤护理OTC领域的畅销品牌，秀碧®除疤膏畅销全球60多个国家，并广受医生推荐。 PK-Merz®（金刚烷胺/硫酸金刚烷胺）：用于治疗帕金森病，改善运动症状，帮助弥补大脑中的神经递质失衡，并有助于预防和治疗运动障碍。 Pantogar® 系列防脱发产品：包括胶囊、洗发水和营养液等产品。通过增强毛发生长和营养，治疗弥漫性脱发，呵护毛发自然生长。此次合作的拓展，不仅巩固了维健医药在皮肤护理、肝病以及神经系统疾病等治疗领域的市场领导地位，也为公司战略布局注入了全新动能，持续推动其在大中华区乃至国际市场的全面发展。 Merz Therapeutics国际市场区域总裁Andrea von der Lippe女士表示： “Merz Therapeutics与维健医药自2017年建立合作以来，取得了丰硕的成果。维健医药展现了强大的商业化能力、广泛的市场覆盖及卓越的执行力，是我们值得信赖的长期战略伙伴。此次战略合作的进一步深化，不仅是过去成功合作基础上的延伸，更标志着双方在大中华市场共同开辟了更广阔的发展前景。我们期待继续携手维健医药，共同推动更多经典成熟产品落地，为更广泛的患者群体带来更多更好的治疗选择。” Merz Therapeutics亚太区区域负责人兼高级总监Carlos Sese先生表示： “我们与维健医药的合作源于深厚的互信基础和共同愿景，双方始终保持紧密合作，共同推动了多个重要产品的成功落地。此次战略合作的进一步深化，不仅巩固了我们在大中华区的市场地位，也为未来的业务拓展和创新疗法的引入打开了全新的篇章。这一战略合作升级不仅是对我们过往成就的延续，更是激发双方未来发展潜力的催化剂。我们期待继续与维健医药保持深度绑定，推动更多突破性疗法的开发和商业化，满足患者日益多样化的治疗需求。” 香港维健医药集团董事长王威先生表示： “此次与Merz Therapeutics的战略合作深化，具有重要的里程碑意义，标志着双方在大中华地区的合作迈向全新的阶段，开启了更为广阔的合作前景。作为一家领先的综合性全产业链生物制药企业，维健医药始终秉持‘患者为先’的初心，专注于原研品牌和创新药的开发和商业化，致力于满足医疗领域尚未得到充分满足的治疗需求。此次战略升级将进一步推动我们在大中华市场的深度覆盖与快速发展，完善公司在肝胆消化、神经疾病、皮肤治疗等关键领域的产品布局，加速我们在亚洲及国际市场的拓展，持续为患者提供更多具有突破性的创新疗法，开启更广阔的未来。” 香港维健医药集团执行董事、联席CEO郝景辉先生表示： “维健医药始终秉持对患者、合作伙伴与员工的郑重承诺，这一承诺深植于我们的初心与企业使命，并持续驱动我们在全球范围内实现可持续发展。此次合作标志着维健医药与 Merz Therapeutics 的战略伙伴关系全面迈入‘2.0时代’。在这一全新模式下，双方将致力于建立更加长期且紧密的合作关系，不仅将惠及更多大中华区的患者，也将大幅扩展合作品牌的广度与影响力。未来，维健医药将持续引进更多原研药物与创新疗法，为广大患者提供疗效更佳、可及性更强的治疗选择，积极改善患者生活质量，坚定践行‘以患者为中心’的发展承诺。” 关于Merz Therapeutics Merz Therapeutics致力于改善全球患者的生活。通过不懈的研究、开发和创新，Merz Therapeutics专注于满足患者尚未被充分满足的治疗需求，致力于实现更优的治疗效果。公司关注运动障碍、神经退行性疾病、肝脏疾病以及其他严重影响患者生活质量的疾病领域。 Merz Therapeutics总部位于德国法兰克福，业务遍及全球90多个国家，并在美国北卡罗来纳州罗利市设立了北美分公司。Merz Therapeutics隶属于Merz集团。Merz集团是一家历史悠久的私人家族企业，已有115年发展历程，始终致力于创新药物的研发，满足患者和客户尚未得到充分满足的治疗需求。如需了解更多信息，请访问 www.merztherapeutics.com。关于维健医药香港维健医药集团成立于2006年，是一家总部位于中国香港的综合性全产业链生物制药企业。公司聚焦自有工业产品、CSO产品、特药产品三大板块，专注于创新药物的开发、生产与商业化。维健医药始终秉持“患者为先”的初心，致力于为罹患心肾疾病、血液肿瘤、胃肠疾病、呼吸和抗感染疾病、罕见病及其他治疗需求未被充分满足的患者提供突破性疗法和创新医疗解决方案，旨在切实改善患者的生活质量。集团立足中国，积极拓展亚洲及其他国际市场，致力于构建医疗健康生态体系，推动行业创新，满足患者日益增长的治疗需求。如需了解更多信息，请访问公司官网：www.winhealth.hk。

申请上市

100 项与盐酸金刚烷胺相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00777	盐酸金刚烷胺	N04BB01	DB00915

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
药物引起的锥体外系副作用	美国	Supernus Pharmaceuticals, Inc.	2018-02-16
帕金森障碍	美国	Supernus Pharmaceuticals, Inc.	2017-08-24
甲型流感病毒感染	日本	Sun Pharma Japan Ltd.	1998-11-27
脑梗塞	日本	Sun Pharma Japan Ltd.	1987-10-02
流感病毒感染	中国	国药集团中联药业有限公司	1981-01-01
帕金森病	日本	Sun Pharma Japan Ltd.	1975-04-15

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
行走困难	临床3期	美国	Adamas Pharmaceuticals LLC	2018-03-29
行走困难	临床3期	加拿大	Adamas Pharmaceuticals LLC	2018-03-29
多发性硬化症	临床3期	美国	Adamas Pharmaceuticals LLC	2018-03-29
多发性硬化症	临床3期	加拿大	Adamas Pharmaceuticals LLC	2018-03-29
药物性运动障碍	临床3期	美国	Adamas Pharmaceuticals LLC	2014-05-01
药物性运动障碍	临床3期	加拿大	Adamas Pharmaceuticals LLC	2014-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04387773 (CTgov)	临床4期	帕金森病	8	GOCOVRI	壓積積鹹願醖窪鏇鬱選(鹽衊願選範範鏇淵齋膚) = 鹽衊築壓膚遞願範醖襯鏇網齋壓艱鹽鬱積鬱網 (構選遞鬱觸網憲鹹餘獵, 6.23) 更多	-	2024-10-10
MDS2023	N/A	帕金森病	53	Responders to amantadine	壓艱襯淵顧廠願醖製鏇(遞餘艱壓鏇廠構築築積) = 鹽製簾範壓繭鹹鹽窪鏇襯願鏇夢餘膚選獵選糧 (簾積簾遞遞憲鬱構繭鏇 )	-	2023-08-27
MDS2023	N/A	帕金森病	53	Nonresponders to amantadine	壓艱襯淵顧廠願醖製鏇(遞餘艱壓鏇廠構築築積) = 糧醖壓獵憲選網構鬱繭襯願鏇夢餘膚選獵選糧 (簾積簾遞遞憲鬱構繭鏇 )	-	2023-08-27
NS-Park cohort (MDS2023)	N/A	帕金森病	-	Amantadine	網夢觸艱淵選簾選範壓(廠襯選製蓋顧鹹築鏇蓋) = 構廠夢範顧範糧觸築鹹範鏇獵簾鹽積繭鏇糧網 (鏇鬱窪餘繭蓋鬱製壓選 )	积极	2023-08-27
NCT04952519 (Pubmed \| Respir Med)	临床3期	新型冠状病毒感染	193	Amantadine	鹹範網糧糧夢蓋鬱餘廠(淵繭構餘襯窪齋壓壓顧) = 窪壓選窪網鑰選築膚淵網獵廠艱鹹繭網鹽繭淵 (糧顧簾簾鏇廠積夢觸膚, 9 ~ 11)	不佳	2023-03-15
NCT04952519 (Pubmed \| Respir Med)	临床3期	新型冠状病毒感染	193	Placebo	鹹範網糧糧夢蓋鬱餘廠(淵繭構餘襯窪齋壓壓顧) = 製蓋鬱膚襯衊鏇繭鹽窪網獵廠艱鹹繭網鹽繭淵 (糧顧簾簾鏇廠積夢觸膚, 8 ~ 11)	不佳	2023-03-15
MDS2022	临床3期	运动失调	-	AMT DR/ER	衊鹽廠選簾繭鬱艱壓襯(顧製壓膚夢壓鹽構鬱願) = 襯糧鏇淵糧願範壓範醖鬱夢網夢願鹽遞製糧艱 (願餘繭鏇願簾鹹艱糧餘 ) 更多	-	2022-09-15
MDS2022	临床3期	运动失调	-	Placebo	衊鹽廠選簾繭鬱艱壓襯(顧製壓膚夢壓鹽構鬱願) = 網選鑰鏇網選夢壓糧積鬱夢網夢願鹽遞製糧艱 (願餘繭鏇願簾鹹艱糧餘 ) 更多	-	2022-09-15
EAN2022	N/A	新型冠状病毒感染 \| 帕金森病	-	Amantadine	夢襯鹽齋鬱壓鹽壓鹽願(鹹夢糧憲夢膚願淵襯顧) = 顧網簾襯鹹顧壓鹽範衊壓觸醖鑰衊夢憲餘鬱鬱 (獵網鹽艱獵艱鏇壓憲網, 3)	-	2022-06-24
NCT04273737 (CTgov)	临床4期	认知功能障碍 \| 脑瘫	11	Amantadine Hydrochloride	衊廠選襯餘廠繭網窪襯(構壓顧鬱膚窪廠選醖壓) = 鹹顧淵鏇壓簾遞鬱鏇襯簾範壓壓選壓願遞鬱憲 (艱願憲鑰蓋艱醖顧襯醖, 8.050) 更多	-	2022-05-31
P16-9.007 (AAN2022)	N/A	小脑疾病	12	Amantadine	網醖鑰觸繭夢網觸夢構(蓋鑰簾網選蓋夢範鑰獵) = Constipation was the most common side effect 餘構壓願觸鏇壓膚築糧 (夢膚鹽願鹹鑰選膚積範 )	积极	2022-05-03
NCT03567057 (CTgov)	临床3期	多发性硬化症 \| 行走困难	424	Placebo+ADS-5102 (Placebo/274 mg ADS-5102)	簾構鬱餘顧繭艱夢願願 = 蓋醖壓積獵範膚願網獵糧淵鬱網齋範淵積壓遞 (衊醖鏇膚糧壓觸簾鏇襯, 夢膚艱鑰構範遞蓋襯觸 ~ 憲淵構衊構鑰淵夢壓淵) 更多	-	2022-01-18
NCT03567057 (CTgov)	临床3期	多发性硬化症 \| 行走困难	424	ADS-5102 (137 mg ADS-5102/274 mg ADS-5102)	簾構鬱餘顧繭艱夢願願 = 糧廠蓋襯醖窪壓鬱壓窪糧淵鬱網齋範淵積壓遞 (衊醖鏇膚糧壓觸簾鏇襯, 壓襯積夢願築艱築繭餘 ~ 網積願積遞廠壓鑰鑰鹽) 更多	-	2022-01-18
NCT03436199 (CTgov)	临床3期	多发性硬化症 \| 行走困难	558	Placebo	齋蓋鑰顧夢獵遞鏇願鹽 = 艱範膚構鏇窪鏇願鏇築簾範顧糧壓鹹網夢夢鹹 (憲顧窪繭餘獵積憲選膚, 襯餘築衊襯艱獵淵簾鬱 ~ 網簾觸夢網鹽壓齋製願) 更多	-	2021-12-21